Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

(2015) Douglas B. Cines et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

(2014) M. Khellaf et al.   BLOOD

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

How Steroids Steer T Cells

(2014) Claude Libert et al.   Cell Reports

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

(2013) S. Gudbrandsdottir et al.   BLOOD

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

(2013) David J. Kuter et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immune thrombocytopenia – what are the new treatment options?

(2013) Simon Hallam et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

(2013) Bahareh Ghadaki et al.   TRANSFUSION

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment

(2012) W. Ghanima et al.   BLOOD

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

(2012) N. Vianelli et al.   HAEMATOLOGICA

Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia

(2012) Mohammad Mashhadi et al.   DARU-Journal of Pharmaceutical Sciences

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

(2010) W. Bao et al.   BLOOD

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production

(2009) Diane Nugent et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Rituximab in the treatment of autoimmune haematological disorders

(2008) Bernadette Garvey   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET